Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 May;6(5):661-7.
doi: 10.4161/cbt.6.5.4003. Epub 2007 Feb 13.

Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors

Yuki Yuza  1 , Karen A Glatt, Jingrui Jiang, Heidi Greulich, Yuko Minami, Michele S Woo, Takeshi Shimamura, Geoffrey Shapiro, Jeffrey C Lee, Hongbin Ji, Whei Feng, Tzu-Hsiu Chen, Haruhiko Yanagisawa, Kwok-Kin Wong, Matthew Meyerson
Affiliations
Free article

Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors

Yuki Yuza et al. Cancer Biol Ther. 2007 May.
Free article

Abstract

Targeted cancer therapies impede cancer cell growth by inhibiting the function of activated oncogene products. Patients with non-small cell lung cancer and somatic mutations of EGFR can have a dramatic response to treatment with erlotinib and gefitinib; different somatic mutations are associated with different times to progression and survival. In this study, the relative and absolute potencies of two distinct EGFR tyrosine kinase inhibitors, erlotinib and an investigational irreversible inhibitor, HKI-272, were found to vary significantly in a panel of Ba/F3 cells transformed by representative EGFR somatic mutations. HKI-272 more potently inhibited the primary exon 20 insertion mutants, the secondary erlotinib-resistance mutants including T790M and many erlotinib-sensitive mutants including L858R. In contrast, erlotinib is a more potent inhibitor of the major exon 19 deletion mutants than is HKI-272. Analyses of EGFR autophosphorylation patterns confirmed the mutation-specific variation in relative potency of these tyrosine kinase inhibitors. Our finding that distinct EGFR inhibitors are more effective in vitro for different mutant forms of the protein suggests that tyrosine kinase inhibitor treatment could be tailored to specific EGFR mutations. More broadly, these results imply that the development and deployment of targeted therapies should focus on inhibition of specific cancer-causing mutations, not only on the mutated target.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms